<DOC>
	<DOCNO>NCT01473797</DOCNO>
	<brief_summary>ECLA phase II , multicenter study test sub cutaneous cladribine 0.1mg/kg/j 5 day , administrate every month 4 course , symptomatic adult patient pulmonary Langerhans cell histiocytosis impairment lung function patient .</brief_summary>
	<brief_title>Evaluation Efficacy Tolerance Cladribine Symptomatic Pulmonary Langerhans Cell Histiocytosis</brief_title>
	<detailed_description>ECLA phase II , multicenter study test sub cutaneous cladribine 0.1mg/kg/j 5 day , administrate every month 4 course , symptomatic adult patient pulmonary Langerhans cell histiocytosis impairment lung function patient .</detailed_description>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Age 18 55 yr Histologically proven pulmonary Langerhans cell histiocytosis ( patient presumptive diagnosis whose lung function precludes lung biopsy may include revision medical record national reference center Langerhans cell histiocytosis ) Symptomatic pulmonary Langerhans cell histiocytosis ( NYHA dyspnea class ≥2 ) : irreversible airflow obstruction ( FEV1/FVC &lt; 70 % ) postbronchodilator FEV1 comprise 30 70 % predict and/or decrease ≥15 % FEV1 , FVC DLCO compare baseline value year precede inclusion Signed write informed consent Women childbearing age without adequate contraception wish breastfeed Male without adequate contraception study Dyspnea due severe pulmonary arterial hypertension ( PAP≥35mmHg ) confirm cardiac right catheterism Previous malignancy Current infectious disease Renal failure Liver failure Severe alteration lung Hematologic disease unrelated Langerhans cell histiocytosis Epilepsy Hepatic , spleen hematology involvement Langerhans cell histiocytosis Pneumothorax within month previously inclusion Previous treatment cladribine Contra indication use cladribine Previous myelosuppressive treatment Simultaneous participation another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>